SureTrader SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Oxford BioMedica PLC (OXBDF)

Add OXBDF Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 1/5/2017 7:51:30 AM - Followers: 5 - Board type: Free - Posts Today: 0

Oxford BioMedica PLC (OXBDF) 
Trades In UK as (OXB.L)
Company website

UK company traded on grey's in US


Company Address:
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom - Map
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001

Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ?wet? age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Financial Reports:
Investor Contacts:
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#381   Jefferies & Co Indicates Potential 92.77% Increase In marcusl2 01/05/17 07:51:30 AM
#380   Trovax HTTP:// Poster Session A: Humora marcusl2 12/30/16 04:33:02 AM
#379   Oxford Biomedica (OXBDF) Given “Buy” Rating at Roth Capital georgejjl 12/09/16 06:54:19 PM
#378   Excellent results, marcusl2 12/04/16 05:24:50 AM
#377   Oxford BioMedica Announces a Strategic Alliance with Orchard Therapeutics marcusl2 11/29/16 08:59:47 AM
#376   Latest results demonstrate that those patients whose immune marcusl2 11/27/16 09:08:31 AM
#375   Seeking Alpha georgejjl 11/21/16 07:55:27 PM
#374 Signing more deals late marcusl2 11/15/16 04:52:35 AM
#373   Novartis` marcusl2 11/07/16 09:36:05 AM
#372   This will rocket if news on Trovax, CTL019 marcusl2 11/04/16 03:22:39 PM
#371   5T4 antibody drug conjugate georgejjl 11/04/16 01:12:05 AM
#370   CART 5T4 georgejjl 11/04/16 01:07:36 AM
#369   HTTP:// marcusl2 11/01/16 05:15:11 AM
#368   CAR-T 5T4 cell therapy: OXB-302 for targeting solid cancer georgejjl 10/24/16 07:29:23 AM
#367   Broker Forecast - Jefferies International issues a broker marcusl2 10/21/16 09:33:05 AM
#366   George, this is interesting; 5T4 oncofoetal antigen: an marcusl2 10/19/16 10:53:37 AM
#365   The patents are baffling to me! marcusl2 10/16/16 08:12:24 AM
#364   Is this a complication or an opportunity? georgejjl 10/16/16 07:56:28 AM
#363   Phase II/III trials look likely with survival end-points marcusl2 10/13/16 04:29:59 AM
#362   Case Studies marcusl2 10/13/16 04:29:15 AM
#361   Oxford BioMedica Announces Publication of Pioneering RetinoStat® (OXB-201) marcusl2 10/10/16 04:43:11 AM
#360   That would be an added bonus George. Let`s marcusl2 10/03/16 10:40:48 AM
#359   I believe that Oxford BioMedica is working on georgejjl 10/01/16 12:42:33 PM
#358   I didn`t see any mention of 5T4 marcusl2 10/01/16 09:52:58 AM
#357   Novartis and Oxford BioMedica's CART therapy for various georgejjl 09/30/16 08:56:02 AM
#356   Just imagine what the new improved version of georgejjl 09/26/16 06:21:28 AM
#355   Pfizer is still interested in 5T4. georgejjl 09/26/16 05:31:47 AM
#354 marcusl2 09/19/16 03:16:24 PM
#353   Thanks George, i`ll re-post that marcusl2 09/16/16 04:24:09 AM
#352   Novartis's new CART therapy for solid tumors georgejjl 09/15/16 10:51:34 PM
#351   Novartis is seeking to clarify misinformation in the marcusl2 09/03/16 06:14:49 AM
#350 marcusl2 08/28/16 12:02:50 PM
#349   HTTPS:// HTTPS:// marcusl2 08/21/16 09:04:57 AM
#348   The market is waiting for clarity on funding marcusl2 08/06/16 05:07:44 PM
#347   The new improved ProSavin trial about to start georgejjl 08/06/16 08:51:15 AM
#346   Yes, first patient due to be treated any marcusl2 08/06/16 06:19:11 AM
#345   The latest news regarding the new improved ProSavin georgejjl 08/04/16 10:49:47 PM
#344   HTTP:// marcusl2 07/30/16 04:47:11 PM
#343 marcusl2 07/28/16 10:01:39 AM
#342 marcusl2 07/14/16 04:02:11 AM
#341   Novartis will pay an upfront fee of $150 marcusl2 06/30/16 10:54:34 AM
#340   The FTSE is up about 2.5% and the georgejjl 06/28/16 07:07:13 AM
#339   News regarding Oxford BioMedica's RetinoStat georgejjl 06/27/16 08:50:07 PM
#338   The LSE and Oxford BioMedica look to be georgejjl 06/27/16 07:23:18 AM
#337   Tim Watts, Chief Financial Officer, will be presenting marcusl2 06/06/16 12:21:45 PM
#336   The way I see it we now have marcusl2 06/04/16 06:55:01 AM
#335   Oxford BioMedica and Green Cross LabCell form a marcusl2 06/02/16 05:51:16 AM
#334   CTL019 Novartis therapy could generate $1.1 billion in marcusl2 06/01/16 11:24:11 AM
#333   SCIENTIFIC BUSINESS marcusl2 05/28/16 06:28:07 AM
#332   It`s evolving quickly George. At least we are marcusl2 05/27/16 03:59:42 AM